

Supplemental tables:**Supplemental Table 1: Percentage of patients with elevated fibrosis biomarkers (>75th percentile) in patients with and without very high ECV.**

Name of the Biomarker	Very high ECV >30 (n=5)	ECV ≤ 30 (n=20)	P value
Galectin-3 (ng/ml)	2 (40%)	3 (15%)	0.23
GDF15 concentration (pg/ml)	1 (20%)	5 (25%)	0.81
PICP (ng/ml)	1 (20%)	5 (25%)	0.81
MMP-1 (pg/ml)	4 (80%)	4 (20%)	0.01
MMP-2 (pg/ml)	3 (60%)	1 (5%)	0.006
MMP-3 (pg/ml)	3 (60%)	2 (10%)	0.02
MMP-8 (pg/ml)	3 (60%)	3 (6%)	0.04
MMP-9 (pg/ml)	2 (40%)	4 (20%)	0.36
MMP-10 (pg/ml)	3 (60%)	3 (6%)	0.04
MMP-13 (pg/ml)	3 (60%)	3 (6%)	0.04
TIMP-1 (pg/ml)	3 (60%)	3 (6%)	0.04
TIMP-2 (pg/ml)	2 (40%)	4 (20%)	0.36
TIMP-4 (pg/ml)	3 (60%)	3 (6%)	0.04

Data is presented as number of patients (%).

Supplemental Table 2: Levels of blood fibrosis biomarkers in patients with and without diffuse myocardial fibrosis and association with ECV.

Name of the Biomarker	All Patients (n=25)	DMF + (n=12)	DMF – (n=13)	P value*	R2	P value**
Galectin-3 (ng/ml)	7 ± 3	7 ± 3	7 ± 3	0.99	0.007	0.68
GDF15 concentration (pg/ml)	582 ± 335	510 ± 247	648 ± 410	0.32	0.007	0.67
ICTP (ng/ml)	65 ± 13	63 ± 18	66 ± 9	0.6	0.0009	0.89
PICP (ng/ml)	359 ± 206	224 ± 54	291 ± 289	0.42	0.004	0.75
MMP-1 (pg/ml)	871 ± 2851	1181 ± 341	3937 ± 1091	0.64	0.008	0.67
MMP-2 (pg/ml)	9178 ± 10105	9672 ± 11099	8722 ± 9969	0.82	0.003	0.8
MMP-3 (pg/ml)	3504 ± 5175	3388 ± 4481	3612 ± 6112	0.92	0.0001	0.99
MMP-8 (pg/ml)	318 ± 698	533 ± 974	239 ± 66	0.41	0.088	0.15
MMP-9 (pg/ml)	13038 ± 12774	7149 ± 2063	17012 ± 7149	0.61	0.004	0.75
MMP-10 (pg/ml)	146 ± 332	247 ± 465	54 ± 111	0.19	0.09	0.14
MMP-13 (pg/ml)	1735 ± 3885	1680 ± 3472	1786 ± 4515	0.95	0.0009	0.88
TIMP-1 (pg/ml)	1217 ± 181	1248 ± 242	1187 ± 112	0.44	0.11	0.09
TIMP-2 (pg/ml)	6855 ± 1123	7127 ± 1299	6605 ± 968	0.27	0.04	0.31
TIMP-4 (pg/ml)	1590 ± 1747	1315 ± 974	1844 ± 2313	0.46	0.005	0.73

GDF-15: Growth differentiation factor-15, ICTP: Type I collagen degradation product, PICP: procollagen type I carboxy terminal peptide, MMP: Matrix

Metalloproteinase, TIMP: Tissue inhibitor of metalloproteinase-1. Results are presented as mean ± standard deviation. *P values from t-test for normally

distributed values and Wilcoxon test for variables without normal distribution. **P values from Pearson test for normally distributed variables and spearman test

for variables without normal distribution.

Supplemental Table 3: Liver shear stiffness (kPa) in patients with elevated fibrosis biomarkers.

Name of the Biomarker	Elevated Biomarker > 75 th Percentile		P value*
	Yes	No	
Galectin-3	4.0 ± 1.3 kPa	4.1 ± 0.7 kPa	0.92
GDF15 concentration	3.7 ± 0.7 kPa	4.2 ± 0.7 kPa	0.34
ICTP	4.1 ± 0.7 kPa	3.6 ± 0.9 kPa	0.56
PICP	4.4 ± 0.4 kPa	3.9 ± 0.8 kPa	0.16
MMP-1	4.6 ± 0.3 kPa	3.9 ± 0.8 kPa	0.02
MMP-2	4.7 ± 0.3 kPa	4.0 ± 0.8 kPa	0.11
MMP-3	4.7 ± 0.2 kPa	3.9 ± 0.7 kPa	0.008
MMP-8	4.6 ± 0.3 kPa	3.9 ± 0.8 kPa	0.02
MMP-9	4.0 ± 0.9 kPa	4.1 ± 0.8 kPa	0.76
MMP-10	4.6 ± 0.3 kPa	3.9 ± 0.8 kPa	0.02
MMP-13	4.6 ± 0.3 kPa	3.9 ± 0.8 kPa	0.02
TIMP-1	4.2 ± 0.8 kPa	4.0 ± 0.8 kPa	0.72
TIMP-2	4.3 ± 0.3 kPa	4.0 ± 0.8 kPa	0.37
TIMP-4	4.7 ± 0.2 kPa	3.9 ± 0.7 kPa	0.008